ARDELYX, INC. (ARDX) Debt Components
- 2026-06-30: Long-term DebtUSD $251.82M; Debt Instrument, Fee AmountUSD $4.84M; Long-term Debt, GrossUSD (m); Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $3.02M.
- 2026-03-31: Long-term DebtUSD $203.52M; Debt Instrument, Fee AmountUSD $4.55M; Long-term Debt, GrossUSD (m); Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $1.03M.
- 2025-12-31: Long-term DebtUSD $202.83M; Debt Instrument, Fee AmountUSD $3.96M; Long-term Debt, GrossUSD (m); Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $1.13M.
- 2025-09-30: Long-term DebtUSD $202.14M; Debt Instrument, Fee AmountUSD $3.36M; Long-term Debt, GrossUSD (m); Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $1.23M.
ARDELYX, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Debt Instrument, Fee Amount USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Line of Credit Facility, Capacity Available for Specific Purpose Other than for Trade Purchases USD | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Periodic Payment, Principal USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $251.82M | $4.84M | (m) | $3.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $203.52M | $4.55M | (m) | $1.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $202.83M | $3.96M | (m) | $1.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $202.14M | $3.36M | (m) | $1.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $201.45M | $2.77M | (m) | $1.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $151.30M | $2.37M | (m) | $1.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $150.85M | $1.99M | (m) | $1.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $100.71M | $3.30M | $104.95M | $944.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $100.25M | $3.65M | $104.95M | $1.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $99.83M | $4.00M | $104.95M | $1.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $49.82M | $734.00K | (m) | $912.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $52.48M | (m) | (m) | (m) | $0.00 | $0.00 | $0.00 | $52.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $27.23M | $355.00K | $28.86M | $1.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $27.05M | $529.00K | $28.86M | $1.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $26.88M | $699.00K | $28.86M | $1.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $26.71M | $1.04M | $28.86M | $1.11M | (m) | (m) | $0.00 | $7.64M | $9.17M | $9.17M | $2.89M | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $26.54M | $1.14M | $28.86M | $1.19M | $26.54M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $26.37M | $1.23M | $28.86M | $1.26M | $26.37M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $26.14M | $1.32M | $28.86M | $1.40M | $26.14M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | $32.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $32.26M | $532.00K | $33.03M | $235.00K | (m) | (m) | $33.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $51.48M | $692.00K | $52.48M | $307.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $51.24M | $853.00K | $52.48M | $378.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $51.02M | $1.01M | $52.48M | $449.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $50.79M | (m) | $52.48M | $518.00K | (m) | (m) | $4.17M | $48.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $50.68M | (m) | $51.98M | $467.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $50.45M | (m) | $51.98M | $561.00K | (m) | (m) | (m) | $25.00M | $24.89M | (m) | (m) | (m) | $2.08M | (m) | (m) | (m) | (m) |
| 2020-03-31 | $50.23M | (m) | $51.98M | $652.00K | (m) | (m) | (m) | $25.00M | $24.89M | (m) | (m) | (m) | $2.08M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $50.01M | (m) | $51.98M | $741.00K | (m) | (m) | $2.08M | $25.00M | $24.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $51.98M | (m) | (m) | $827.00K | (m) | (m) | (m) | $2.08M | $25.00M | $24.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $51.98M | (m) | (m) | $911.00K | (m) | (m) | (m) | $2.08M | $25.00M | $24.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $51.98M | (m) | (m) | $991.00K | (m) | (m) | (m) | $2.08M | $25.00M | $24.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $51.98M | (m) | (m) | $1.09M | (m) | (m) | (m) | $2.08M | $25.00M | $24.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $51.98M | (m) | (m) | $1.14M | (m) | (m) | (m) | (m) | $2.08M | $25.00M | $24.89M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $51.98M | (m) | (m) | $1.22M | (m) | (m) | (m) | (m) | $2.08M | $25.00M | $24.89M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-05-16 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $50.00M | (m) | (m) |
| 2018-05-16 | (m) | (m) | $50.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 7.45% | (m) |
| 2018-05-16 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.10M |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $80.00K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |